LY-344545 explained

LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR2/3-selective LY-341,495.[1] [2]

Notes and References

  1. Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M . 6 . 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability . Journal of Medicinal Chemistry . 41 . 3 . 358–78 . January 1998 . 9464367 . 10.1021/jm970498o .
  2. Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL . 6 . A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices . British Journal of Pharmacology . 131 . 2 . 239–44 . September 2000 . 10991916 . 1572327 . 10.1038/sj.bjp.0703574 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "LY-344545".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.